Sarcoma UK is delighted to announce a partnership with RareCan supporting them to build an extensive cohort of member numbers with a sarcoma diagnosis that will improve data and drive research.
The RareCan community is open to anyone over the age of 18, who:
- would like to access more information about rare cancers
- have access to a suite of digital tools to help them manage their diagnosis
- share information about their experiences
- support research in the future
Sarcoma UK is now one of the biggest funders of sarcoma research in the UK, having invested more than £5 million to 74 research projects to date. The charity has helped more than 3200 individuals through support services an average of three times since it launched it in February 2016. Sarcoma UK relies on generous voluntary donations and the energy and imagination of its tireless fundraisers.
RareCan is a digital health company, building a community of members who are willing to share information about their cancer. It gives power to patients and a voice to share while at the same time building cohorts, so that researchers can find them in a keystroke. Established in 2020, RareCan also offers a suite of tools, co-designed by its members, to help support them manage their lives as they live with their rare cancer.
Rare and less common cancers, including sarcoma account for almost a ¼ of cancer cases in the UK. Given the 5,300 people diagnosed with a sarcoma every year, giving patients the opportunity to be found in one place means that it will be quicker to find cohorts of the same cancer type by people who are already willing to be contacted to take part in research.
Piers Kotting, RareCan CEO says ‘We are thrilled to be working with Sarcoma UK to help us drive our membership. We regularly refer RareCan members to Sarcoma UK and other charity networks so that they get the valuable support they may need at various points following their cancer diagnosis. Being a member of RareCan enables those who want to participate in research to connect with researchers and help accelerate research.’
Sarah Kingsmill, Information & Content Manager at Sarcoma UK agrees ‘There are only a limited number of sarcoma clinical trials open at any one time. At Sarcoma UK, we want to ensure that all patients have access to clinical trials where possible. By working with RareCan, we hope to build cohorts to accelerate research that will benefit the sarcoma community in the future.’
Join the RareCan community
